DOK3 is involved in microglial cell activation in neuropathic pain by interacting with GPR84

Wen-Shuang Gao1, Yu-Juan Qu1, Juan Huai1

  • 1Rehabilitation Center, Qilu Hospital, Cheeloo College of Medicine, Shandong University, Jinan, China.

Aging
|December 7, 2020
PubMed

Insights

Adaptor protein DOK3 (downstream of kinase-3) activates microglia, driving neuropathic pain through interaction with GPR84. Targeting DOK3 offers a potential therapeutic strategy for spinal cord pain relief.

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Adaptor molecule downstream of kinase-3 (DOK3) regulates innate immunity.
  • G-protein-coupled receptor 84 (GPR84) mediates inflammatory mediators in neuropathic pain.
  • Microglia play a key role in neuroinflammation and pain signaling.

Purpose of the Study:

  • To determine the role of DOK3 in microglia-mediated neuropathic pain.
  • To investigate the underlying mechanisms involving GPR84.
  • To explore DOK3 as a potential therapeutic target for neuropathic pain.

Main Methods:

  • Knockdown of DOK3 in microglial cells.
  • Assessment of inflammatory factor levels.
  • In vivo studies using DOK3 knockout mice and chronic constriction injury (CCI) model.
  • Evaluation of GPR84 agonist effects.
  • Analysis of pregabalin's impact on DOK3 expression.

Main Results:

  • DOK3 knockdown significantly reduced inflammatory factors in microglia.
  • A physical association between DOK3 and GPR84 was identified.
  • Neuropathic pain and inflammation were reduced in DOK3 knockout mice.
  • Pregabalin administration alleviated pain by inhibiting DOK3 expression.

Conclusions:

  • DOK3 induces neuropathic pain via interaction with GPR84 in microglia.
  • Targeting DOK3 presents a promising pharmaceutical approach for neuropathic pain management.
  • This research highlights DOK3 as a key player in spinal cord pain mechanisms.